格利本克拉米德在中风中的神经保护作用:随机对照试验的系统审查和元分析
Guilherme José da Costa Borsatto1, Heitor Pereira Vale da Costa2, Laís Silva Santana2
1School of Medicine, University of Sao Paulo, São Paulo, São Paulo, Brazil. guilherme.borsatto@fm.usp.br.
Acta neurologica Belgica
|July 8, 2025
概括
Glibenclamide 并没有改善急性中风患者的结果,包括功能状态,脑或死亡率. 虽然它增加了低血糖的风险,但进一步的研究可能会确定特定的患者亚组,他们可以从这种潜在的神经保护疗法中受益.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 临床试验 临床试验
背景情况:
- 在全球范围内,中风仍然是死亡和残疾的主要原因.
- 大脑明显恶化了中风患者的结果.
- 硫基氨基酸中的一种glibenclamide具有神经保护潜力,并在临床前模型中减少大脑.
研究的目的:
- 评估Glibenclamide在改善功能结果,减少大脑水和降低急性中风患者的死亡率方面的疗效.
- 分析来自随机对照试验 (RCT) 的数据,用于急性缺血性中风 (AIS),脑内出血 (ICH) 和动脉瘤下关节出血 (aSH).
主要方法:
- 对7项涉及1,225名患者的RCT进行了系统审查和元分析.
- 在急性中风管理中,glibenclamide与标准护理的比较.
- 功能状态的评估 (mRS 0-3在3个月),脑 (中线转移在72-96小时),死亡率和低血糖事件.
主要成果:
- 在AIS和aSH患者中,glibenclamide在3个月后没有改善功能结果.
- 在ICH患者中观察到适度的功能益处 (RR=1.16;95% CI:1.04-1.28)).
- 在AIS中没有发现大脑的显著减少. 死亡率没有变化,但低血糖的风险增加 (RR=3.57;95% CI:1.19-10.68).
结论:
- 在整体急性中风患者中,glibenclamide对功能结果,脑或死亡率没有显著的益处.
- 低血糖症的风险增加与glibenclamide使用有关.
- 需要进一步的研究来确定特定的患者亚组,这些患者可能会受益于glibenclamide作为神经保护剂.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Antiepileptic Drugs: GABAergic Pathway Potentiators
665
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
665
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309


